Skip to main content

Gadobenate dimeglumine Side Effects

Medically reviewed by Last updated on Sep 11, 2023.

Applies to gadobenate dimeglumine: intravenous solution.


Intravenous route (Solution)

Nephrogenic Systemic Fibrosis (NSF)Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73 m(2)) or acute kidney injury.Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, age greater than 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.For patients at highest risk for NSF, do not exceed the recommended gadobenate dimeglumine dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration

Serious side effects

Along with its needed effects, gadobenate dimeglumine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking gadobenate dimeglumine:


Incidence not known

Other side effects

Some side effects of gadobenate dimeglumine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common


For Healthcare Professionals

Applies to gadobenate dimeglumine: intravenous solution.


Cardiovascular side effects have included hypertension, vasodilatation, and tachycardia.[Ref]


Gastrointestinal side effects have included nausea, vomiting, and diarrhea.[Ref]


Hematologic side effects have included anemia.[Ref]

Nervous system

Nervous system side effects have included headache, paresthesia, and dizziness.[Ref]


Dermatologic side effects have included rash.[Ref]


General side effects have included taste perversion.[Ref]


Local side effects have included pain and injection site reactions.[Ref]


Hypersensitivity side effects have included anaphylactic and anaphylactoid reactions involving cardiovascular, respiratory and/or cutaneous manifestations which ranged from mild to severe. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of administration and resolved with prompt emergency treatment.


1. Product Information. Multihance (gadobenate dimeglumine). Bracco Diagnostics Inc. 2005.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.